Hospital Clínic de Barcelona / IDIBAPS
Barcelona's university hospital, home of the BCLC liver cancer staging system, the first European academic CAR-T and leading breast and lymphoma genomics.
Hospital Clínic and its research institute IDIBAPS form one of Spain's strongest academic medical centres. The Barcelona Clinic Liver Cancer group of Jordi Bruix and Josep Maria Llovet created the BCLC staging and treatment algorithm and led the SHARP trial that made sorafenib the first systemic therapy for hepatocellular carcinoma. Elías Campo's group mapped the genome of chronic lymphocytic leukaemia within the ICGC and co-edits the WHO haematolymphoid classification, Aleix Prat's group advanced intrinsic subtyping (PAM50, HER2DX) in breast cancer, and the hospital's ARI-0001 CD19 CAR-T, developed by Manel Juan and Álvaro Urbano-Ispizua, became the first academic CAR-T authorised in Europe under Spain's hospital exemption in 2021. The centre is OECI-accredited and runs a large early-phase and haematology programme.
- BCLC liver cancer group
- Academic CAR-T (ARI-0001, ARI-0002h)
- Lymphoid neoplasm genomics
- Breast cancer intrinsic subtypes
- Early-phase trials
Pages like this
not linked directly; found by shared links- IdeaHospital-made CAR-T under one shared regulatory master file
Shares BCMA, CD19, Prices and value, Manufacturing cost and time for living and radioactive medicines.
- IdeaHospital-based CAR-T manufacturing at cost through a public network
Shares BCMA, CD19, Prices and value, Manufacturing cost and time for living and radioactive medicines.
- InstitutionHadassah Medical Center
Shares BCMA, CD19, Manufacturing cost and time for living and radioactive medicines, Multiple myeloma.
- IdeaPlan the second CAR-T target before the first one is lost
Shares BCMA, CD19, Manufacturing cost and time for living and radioactive medicines, Multiple myeloma.
- IdeaNon-profit, open-licence lentiviral vectors and producer cell lines for CAR-T
Shares BCMA, CD19, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- IdeaIn vivo CAR-T manufactured and priced like a generic biologic
Shares BCMA, CD19, Prices and value, Manufacturing cost and time for living and radioactive medicines.
- InstitutionSOLTI Cancer Research Group
Shares PAM50 / intrinsic subtypes, Vall d'Hebron University Hospital / VHIO, RNA sequencing & expression profiling, HR-positive / HER2-negative breast cancer.
- InstitutionSkåne University Hospital / Lund University Cancer Centre
Shares PAM50 / intrinsic subtypes, RNA sequencing & expression profiling, Whole-exome & whole-genome sequencing, HR-positive / HER2-negative breast cancer.